Chaisson R E, Leuther M D, Allain J P, Nusinoff-Lehrman S, Boone G S, Feigal D, Volberding P
Medical Service, San Francisco General Hospital.
Arch Intern Med. 1988 Oct;148(10):2151-3.
We assessed the effect of antiviral therapy on serum human immunodeficiency virus core antigen (HIV-Ag) levels in patients enrolled in the phase II trial on zidovudine for acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Human immunodeficiency virus core antigen was detected in 45% of subjects at entry (59% with AIDS and 37% of patients with AIDS-related complex). Median HIV-Ag levels in zidovudine-treated subjects fell from 111 pg/mL at entry to 46 pg/mL at four weeks, while levels in placebo recipients did not change significantly. Decline in HIV-Ag in zidovudine recipients was sustained through 16 weeks of treatment and was significantly different from the placebo group. Anti-p24 antibody levels did not change in either group. We conclude that in patients with HIV-antigenemia changes in HIV-Ag level are an important marker of anti-retroviral activity.
我们评估了抗病毒治疗对参与齐多夫定治疗获得性免疫缺陷综合征（AIDS）及AIDS相关综合征二期试验患者血清人类免疫缺陷病毒核心抗原（HIV-Ag）水平的影响。入组时，45%的受试者检测到人类免疫缺陷病毒核心抗原（AIDS患者中为59%，AIDS相关综合征患者中为37%）。接受齐多夫定治疗的受试者中，HIV-Ag水平中位数从入组时的111 pg/mL降至四周时的46 pg/mL，而接受安慰剂的受试者水平无显著变化。接受齐多夫定治疗的受试者中，HIV-Ag水平下降持续至治疗16周，且与安慰剂组有显著差异。两组的抗p24抗体水平均未改变。我们得出结论，在患有HIV抗原血症的患者中，HIV-Ag水平的变化是抗逆转录病毒活性的重要标志。
